#362 Dosing low, winning high: unlocking the promise of endothelin antagonism for the treatment of CKD in the zibotentan/dapagliflozin ZENITH trials
Authors: Mercier Anne-Kristina , Ueckert Sebastian , Sunnåker Mikael , Hamrén Bengt , Ambery Philip , Greasley Peter J , Åstrand Magnus 
Published: May 2024

Background and Aims

The Phase 2b ZENITH-CKD trial demonstrated that combined treatment with the endothelin A receptor (ETAR) antagonist zibotentan and the sodium-glucose co-transporter-2 inhibitor (SGLT2i) dapagliflozin yields a robust and significant reduction in albuminuria in individuals with chronic kidney disease (CKD), compared to dapagliflozin treatment alone [1].

This is hypothesized to translate into a significant reduction of kidney function decline and may further confer cardiometabolic benefits including reducing blood pressure, LDL cholesterol and (in type 2 diabetes) HbA1c in the ongoing Phase 3 ZENITH High Proteinuria trial. The usage of ETAR antagonists has until now been limited by the class effect of fluid retention, which is associated with an increased risk of heart failure in the at-risk CKD population. Zibotentan has previously been investigated at 10 mg per day in Phase 3 for the treatment of prostate cancer.

Method

Model-Informed Drug Development (MIDD) was integrated with clinical pharmacology data to develop the dose strategy for both ZENITH trials. A low-dose strategy was selected considering the increased plasma exposure of zibotentan in kidney impairment. The Phase 2b dose steps were selected based on an exposure response model for the efficacy marker urinary albumin to creatinine ratio (uACR) and were supported using clinical trial simulations. The dose strategy for Phase 3 was defined based on a combined analysis of ZENITH-CKD results for both efficacy and tolerability: efficacy (uACR reduction on top of dapagliflozin) was analysed with a Dose-Response Mixed Model for Repeated Measures, and tolerability (fluid retention events, defined as a combination of specified body weight and BNP increase) was evaluated with Kaplan Meier analyses.

Results

Zibotentan doses of 0.25 mg and 1.5 mg (in a first, discontinued study part also 5 mg), in combination with dapagliflozin 10 mg, were selected for ZENITH-CKD. Clinical trial simulations indicated that inclusion of the low dose of 0.25 mg was crucial to characterise the dose-response relationship. Dose-uACR response modelling of ZENITH-CKD data predicted a zibotentan dose of 0.75 mg to result in a mean uACR reduction of around 25% in addition to the reduction with dapagliflozin. A post-hoc regression analysis of uACR mean changes from baseline, stratified by dose, showed a trend towards lower uACR reduction with higher eGFR levels. Kaplan-Meier analyses of the fluid retention risk in different eGFR subgroups indicated that the fluid retention risk increased with increasing zibotentan dose for eGFR levels &lt;45 mL/min/1.73 m2, while for higher eGFR levels, no differences were observed between treatments with dapagliflozin alone and added zibotentan 0.25 mg or 1.5 mg. Therefore, a kidney-function based zibotentan dose strategy was selected for the ZENITH High Proteinuria trial: Combined zibotentan/dapagliflozin is being compared against dapagliflozin alone; within the combination treatment arm, 0.25 mg zibotentan is selected for participants with baseline eGFR levels &lt;45 mL/min/1.73 m2, and 0.75 mg is selected for higher eGFR level, with a tolerance eGFR window for participants whose eGFR declines below this cut-off, and with the possibility to reduce the dose to 0.25 mg in case of tolerability findings.

Conclusion

The favourable benefit/risk profile that was demonstrated for combined zibotentan/dapagliflozin in ZENITH-CKD was enabled by the zibotentan low-dose strategy. The wide dose ranging and MIDD further enabled selection of a kidney-function based zibotentan dosing strategy for ZENITH High Proteinuria which is designed to further balance benefit/risk. The low-dose zibotentan strategy and the combination with dapagliflozin opened for the first time a therapeutic window for ETAR antagonists, with the potential to redefine their value for the treatment of CKD.

This work was sponsored by AstraZeneca.